Results 21 to 30 of about 18,827 (200)

Palbociclib releases the latent differentiation capacity of neuroblastoma cells. [PDF]

, 2023
Neuroblastoma is the most common extracranial solid tumor in infants, arising from developmentally stalled neural crest-derived cells. Driving tumor differentiation is a promising therapeutic approach for this devastating disease.

core   +19 more sources

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Journal of Global Oncology, 2019
PURPOSE: The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer (ABC)
John Waller, Debanjali Mitra, Katie Mycock, Gavin Taylor-Stokes, Gary Milligan, Lin Zhan, Shrividya Iyer   +6 more
doaj   +1 more source

Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2– advanced/metastatic breast cancer in Japan: Results from the IRIS study

Cancer Treatment and Research Communications, 2022
Background: The incidence of breast cancer is rising in Japan, particularly in postmenopausal women. The CDK 4/6 inhibitor palbociclib has demonstrated efficacy in clinical studies in patients with hormone receptor-positive (HR+), human epidermal growth ...
Katie Mycock, Lin Zhan, Kieran Hart, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra   +6 more
doaj   +1 more source

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pharmaceutics, 2022
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet, Evelina Cardoso, Carole Bandiera, Athina Stravodimou, Jean-Philippe Zurcher, Haithem Chtioui, Isabella Locatelli, Laurent Arthur Decosterd, Léa Darnaud, Benoit Blanchet, Jérôme Alexandre, Anna Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka   +15 more
doaj   +1 more source

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma [PDF]

, 2020
Background: Recent genomic analyses revealed that druggable molecule targets were only detectable in approximately 6% of patients with nasopharyngeal carcinoma (NPC).
You, C, Cheung, LWT, Lo, KW, Tsao, SW, YUAN, H, XUE, Z, Jia, L, Lee, VHF, Khong, PL, Lee, AWM, Tsang, CM, Piao, W, Li, Y, Li, X, Lui, VWY   +14 more
core   +1 more source

Combination of palbociclib and radiotherapy for glioblastoma

, 2017
The cyclin-dependent kinase inhibitor, palbociclib has shown compelling efficacy in breast cancer patients. Several pre-clinical studies of glioblastoma (GBM) have also shown palbociclib to be efficacious.
Mustafa Khasraw, Bryan Day, Sylvia A Chung, Kerrie L McDonald, Terrance Johns, Swapna Joshi, Shane Whittaker, Daniel Madani   +7 more
core   +2 more sources

MIMA study - Palbociclib

, 2022
spatially registered images of multiplex IHC staining of MMTV-PyMT mammary carcinoma tissue three days after local Palbociclib drug delivery. Drug release is from the bottom to the top. 
Zuzana Tatarova (12507553)
core   +1 more source

Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population

Technology in Cancer Research & Treatment, 2022
Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently.
Yusi Zhang MS, Wenlin Chen MD, Shuanglong Chen MS, Qingmo Yang MD, Zhong Ouyang MD   +4 more
doaj   +1 more source

Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma

BMC Medicine, 2022
Background Deregulation of cell-cycle pathway is ubiquitously observed in human papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC).
Ziyue Gu, Chaoji Shi, Jiayi Li, Yong Han, Bao Sun, Wuchang Zhang, Jing Wu, Guoyu Zhou, Weimin Ye, Jiang Li, Zhiyuan Zhang, Rong Zhou   +11 more
doaj   +1 more source

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer

Breast, 2021
Background: This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC).
R.K. Ismail, J. van Breeschoten, M.W.J.M. Wouters, M. van Dartel, S. van der Flier, A.K.L. Reyners, P. de Graeff, A.M.G. Pasmooij, A. de Boer, K.E. Broekman, D.L. Hilarius   +10 more
doaj   +1 more source